Navigation Links
Interim Report for the Period 1 January - 30 September 2008 (Unaudited)
Date:11/26/2008

VEDBAEK, Denmark, November 26 /PRNewswire-FirstCall/ -- Exiqon A/S, traded at the NASDAQ OMX Copenhagen ("EXQ"), reports continued strong growth in research product sales during the third quarter of 2008. Revenues were positively affected by the execution of a license agreement with Roche Diagnostics for use of Exiqon's LNA(TM) technology. Initial fourth quarter sales were negatively affected by supply of arrays that failed Exiqon's internal quality tests causing a slow down in executed sales orders. Although the supply problems have now been addressed, Exiqon revises its 2008 total year guidance of revenue of DKK 140-150 million to now DKK 120-130 million. As a result, a net loss of DKK 115-125 is now anticipated compared to previous expectations of a net loss of DKK 100-115 million.

    - Revenue in the third quarter of 2008 increased five fold on the
      year-earlier period to DKK 51.3 million, totaling DKK 95.8 million in
      the first nine months of 2008.

    - Compared third quarter last year product sales increased by 329% to DKK
      28 million totaling DKK 68,5 million in the first nine months of 2008.
      Research product sales grew organically by 141%.

    - Net loss for the third quarter of 2008 was DKK 10.1 million totaling
      DKK 73.6 million in the first nine months of 2008. EPS amounted to DKK
      -0.35 in the third quarter of 2008 and DKK -2.55 in the first nine
      months of 2008.

    - License granted to Roche Diagnostics for use of Exiqon's proprietary
      LNA(TM) detection technology in a new product line for RealTime ready
      qPCR assays demonstrates the value of LNA(TM) as a detection
      technology.

    - The integration of former Oncotech Inc - now Exiqon Diagnostics Inc -
      remains on track for the first miRNA diagnostic product launch to be
      announced in December 2008.

Lars Kongsbak, President and CEO says: "Product demand remains stron
'/>"/>

SOURCE Exiqon A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Interim Analysis of Top-Line Data From Phase II/III Study Shows Favorable Efficacy & Safety for Cortheras Relaxin in Acute Heart Failure
2. Interim Analysis of Data from e-HEALING Registry of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented at AHA Scientific Sessions 2008
3. Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data
4. Misonix Announces Interim Distribution Agreement for Italy
5. Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure
6. Exiqon A/S: Interim Report for the Period 1 January - 30 June 2008 (Unaudited)
7. Arpida Reports Interim Results for Six Months to 30 June 2008
8. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
9. LPBP Inc. - Re-filing certification of interim filings
10. Fufeng Announces 2008 Interim Results With Strong Sign of Recovery
11. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... July 21, 2015 ... the addition of the "Analysis of the ... their offering. Globally, flow cytometry remains ... cell proliferation, cancer, and stem cells. But the ... primarily because of demand from underdeveloped nations to ...
(Date:7/28/2015)... 21, 2015 Research and Markets ( ... "Biomedical Refrigerators and Freezers Market - Global ... 2014 - 2022" report to their offering. ... freezers market has been segmented based on applications: ... and others. The others segment includes applications of ...
(Date:7/28/2015)... , ... July 28, 2015 , ... VetStem Biopharma will ... stem cell credentialing course to local area veterinarians. , The tour and course will ... units at no charge) at VetStem’s Poway facility. Staff members are welcome to attend ...
(Date:7/28/2015)... YORK , July 28, 2015 Deerfield ... Deerfield Healthcare Innovations Fund, L.P., which will invest in ... interventions in genetic diseases, cancer, and orphan diseases. The ... can transform how therapeutics are developed and improve the ... fund, one of the largest healthcare-focused venture funds in ...
Breaking Biology Technology:Analysis of the Global Flow Cytometry Market 2012-2018 with a 2014 Base Year and a 2015-2018 Forecast Period 2Biomedical Refrigerators and Freezers Market Report - Global Industry Analysis 2015 2Biomedical Refrigerators and Freezers Market Report - Global Industry Analysis 2015 3VetStem Biopharma weekly veterinary continuing education classes and GMP manufacturing facility tour 2Deerfield Launches $550 Million Healthcare Venture-Capital Fund 2Deerfield Launches $550 Million Healthcare Venture-Capital Fund 3
... chooses AMICAS to drive improvements in customer ... service and operational efficiency, ... leader in radiology and medical image and information management,solutions, today ... California,s most influential radiology groups., (Logo: http://www.newscom.com/cgi-bin/prnh/20060202/AMICASLOGO ...
... July 28 Ranbaxy,Pharmaceuticals Inc. (RPI), a ... Gurgaon, India announced today that under an,agreement ... authorized,generic of Omeprazole 40 mg Capsules in ... indicated for the treatment of acid-related disease,including ...
... Pa., July 25 BioTrends Research Group, Inc.,released ... offering comprehensive insight into the management of,renal anemia ... Disease,(CKD) and Dialysis. The report provides information from ... online survey fielded in,June 2008., In the ...
Cached Biology Technology:Arcadia Radiology Medical Group Chooses AMICAS 2Arcadia Radiology Medical Group Chooses AMICAS 3Ranbaxy Launches Omeprazole 40 mg Capsules 2BioTrends Releases Quarterly TreatmentTrends(TM): Nephrology Report Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism 2BioTrends Releases Quarterly TreatmentTrends(TM): Nephrology Report Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism 3
(Date:7/8/2015)... YORK , July 8, 2015 Summary ... globally, and the fourth most fatal, with a mortality ... The poor prognosis of pancreatic cancer patients has highlighted ... treatment, which is not being met by the current ... an array of products with varying molecule types and ...
(Date:7/8/2015)... -- The consumer products industry for innovative tech ... such as wearables, smart wallets & other smart technology are ... continues to rapidly grow.  Biometrics & Wearable Device Companies in ... Inc. (NASDAQ: GOOG ), Apple Inc. (NASDAQ: AAPL ... GPRO ) and Baidu Inc. (NASDAQ: BIDU ) ...
(Date:7/7/2015)... Conn. , July 7, 2015 NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market announces a revised version ... this week. The commercial will air on CNBC in ... Los Angeles and San Francisco ... The commercial focuses on Wocket,s ability to replace all the cards ...
Breaking Biology News(10 mins):Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 2Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 4Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 5Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 6Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
... Osteoporosis Foundation (IOF) is pleased to announce the inaugural ... best pre-clinical and translational science in bone biology to ... European Congress on Osteoporosis and Osteoarthritis (ECCEO11-IOF) in Valencia ... Karsenty, Professor and Chair, Genetics & Development, Columbia University ...
... likely to alter plant diseases of the future. Researchers ... the preindustrial era by the year 2050, complicating agriculture,s ... population. University of Illinois researchers are studying ... higher atmospheric temperatures on plant diseases that could challenge ...
... University of Leicester will use the latest genetic techniques ... disease. The study will help to identify new ... This, in turn may help to develop new diagnostic ... by postgraduate researcher Paraskevi Christofidou, of the Department of ...
Cached Biology News:Climate change complicates plant diseases of the future 2Climate change complicates plant diseases of the future 3How genetic 'chips' could help to understand heart disease 2
... power of your ValveBank system! Program your ... computer running Windows 98, 2000, XP using graphic ... disk, print out program listings, then download your ... step., EasyCode is used for programming before -- ...
... DNA Ligase catalyzes the formation of phosphodiester ... double-stranded DNAs with 3' hydroxyl and 5' ... buffer optimizes ligation which can be performed ... are not substrates for this enzyme. ...
... is a major step forward in ... handling system - with one universal ... modules. All five single channel and ... one handle. The lightweight handle is ...
alpha-N-Catenin Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Biology Products: